How to Get Addyi (Flibanserin) in Florida

What Addyi Is and Why It Requires a Special Prescribing Process

Addyi (flibanserin) is the only FDA-approved non-hormonal oral medication for hypoactive sexual desire disorder in premenopausal women. The FDA granted approval in August 2015 after the agency reviewed three key Phase 3 trials, including BEGONIA (N=1,378), which showed that women taking flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events versus placebo (P<0.001) over 24 weeks [1]. A second key trial, SNOWDROP, enrolled postmenopausal women and found a similar efficacy signal, though the current FDA label restricts the indication to premenopausal status [2].

Because flibanserin carries a boxed warning for severe hypotension and syncope when combined with alcohol or certain CYP3A4 inhibitors, the FDA requires prescribers and pharmacies to enroll in the Addyi REMS (Risk Evaluation and Mitigation Strategy) program before dispensing [3]. Patients sign a Patient-Prescriber Agreement confirming they understand the alcohol restriction. This step adds about five minutes to the intake process but does not require any specialized facility or in-person visit under current Florida telehealth rules.

HSDD affects roughly 8-10% of premenopausal women in the United States, according to epidemiological data published in Obstetrics and Gynecology [4]. The condition is defined by the DSM-5 criterion of persistently low sexual desire that causes marked personal distress, and it must not be attributable to a relationship problem, another medical condition, or a medication side effect before flibanserin is appropriate [5].

Florida Telehealth Rules for Flibanserin Prescribing

Florida explicitly permits telehealth prescribing of controlled and non-controlled medications, including flibanserin, under Section 456.47 of the Florida Statutes. Flibanserin is not a controlled substance, which removes the DEA registration barrier that applies to drugs like testosterone or buprenorphine.

A telehealth provider in Florida must hold an active Florida license or a Florida telehealth registration. The consultation may occur via synchronous video, and some platforms accept asynchronous (store-and-forward) intake for REMS-enrolled medications, though the REMS Patient-Prescriber Agreement must still be reviewed during the visit. The Florida Board of Medicine does not prohibit prescribing flibanserin at a first telehealth visit, provided the provider conducts an adequate clinical evaluation.

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 659 states: "Clinicians should be prepared to evaluate and manage women with sexual dysfunction, including HSDD, in the context of their overall health and relationship status" [6]. Telehealth platforms that specialize in women's sexual health have built REMS enrollment workflows directly into their intake forms, making the prescribing pathway faster than a traditional office setting in many cases.

After the consult, the provider sends an electronic prescription to any REMS-enrolled pharmacy in Florida or to a REMS-enrolled mail-order pharmacy that ships to Florida addresses. Typical turnaround from completed consult to dispensed medication is 48-72 hours for mail delivery and same-day or next-day for local pharmacy pickup when stock is available.

Who Can Prescribe Addyi in Florida

Any Florida-licensed prescriber who has completed REMS enrollment may write a flibanserin prescription. That includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) holding an active Florida license.
• Advanced practice registered nurses (APRNs) / nurse practitioners (NPs) practicing under a supervising or collaborating physician agreement as required by Florida Statute 464.
• Physician assistants (PAs) working under a supervising physician per Florida Statute 458.347.

The REMS program does not impose additional credentialing beyond standard licensure. Prescribers complete a brief online enrollment, confirm they understand the drug-alcohol interaction, and agree to counsel patients before each prescription. As of 2024, more than 40,000 healthcare providers in the United States were REMS-enrolled for Addyi, according to Sprout Pharmaceuticals [7].

Gynecologists, primary care physicians, and women's health NPs are the most common prescribers. Psychiatrists occasionally prescribe it when HSDD co-occurs with a mood disorder, provided they have confirmed the low desire is not purely a medication side effect from an SSRI or SNRI.

Step-by-Step: Getting an Addyi Prescription in Florida

Step 1. Schedule a telehealth or in-person consult. Choose a Florida-licensed provider enrolled in the Addyi REMS. Telehealth platforms focused on women's sexual health often allow same-week appointments. In-person gynecology offices typically have 2-4 week wait times.

Step 2. Complete the intake questionnaire. Most platforms ask you to fill out a validated screening tool such as the Female Sexual Function Index (FSFI) or the DSDS (Decreased Sexual Desire Screener) before the visit. These take 5-8 minutes and help the provider establish the HSDD diagnosis in your medical record.

Step 3. Attend the clinical consultation. The provider reviews your sexual and medical history, rules out secondary causes of low desire (thyroid dysfunction, depression, relationship distress, medication side effects), and discusses the alcohol restriction. You sign the REMS Patient-Prescriber Agreement electronically.

Step 4. Receive the prescription. The provider sends the Rx electronically to your chosen REMS-enrolled pharmacy in Florida or a mail-order pharmacy that ships to your zip code.

Step 5. Fill and begin therapy. Take 100 mg at bedtime only. Do not take it during waking hours; daytime dosing increases dizziness and hypotension risk. If you see no benefit after 8 weeks of consistent nightly use, current labeling recommends discontinuing [3].

Lab Work and Medical Evaluation Before Starting Flibanserin in Florida

Flibanserin does not require the same pre-treatment laboratory panel as hormone therapies. The FDA label does not mandate any specific blood tests before initiation [3]. In clinical practice, however, providers commonly order the following to rule out secondary causes of low libido:

• Thyroid-stimulating hormone (TSH): Hypothyroidism is a common and correctable cause of low sexual desire. The American Thyroid Association recommends TSH as the first-line test for suspected thyroid dysfunction [8].
• Free and total testosterone: Low androgen levels may contribute to HSDD and could indicate a candidate for off-label testosterone therapy rather than, or in addition to, flibanserin.
• Prolactin: Hyperprolactinemia suppresses libido and can be caused by a pituitary adenoma or by dopamine-blocking medications.
• Complete metabolic panel (CMP): Liver function is relevant because flibanserin is primarily metabolized by CYP3A4 in the liver, and hepatic impairment is a contraindication [3].
• Depression screening (PHQ-9): HSDD must be distinguished from low desire secondary to major depressive disorder before prescribing.

None of these labs must be drawn at a specific Florida lab chain. Telehealth providers typically send orders to LabCorp, Quest Diagnostics, or BioReference locations near the patient. Results are usually available within 24-48 hours and can be uploaded to the patient portal before or after the consult depending on the platform's workflow.

If all secondary causes are excluded and the patient meets DSM-5 criteria for HSDD, flibanserin is appropriate to prescribe without waiting for additional workup. The BEGONIA trial enrolled women who had already been screened for secondary causes, and participants reported a mean increase of 0.7 satisfying sexual events per month above placebo at week 24 [1].

Flibanserin Pharmacies in Florida: Retail, Mail-Order, and 503A Compounding

REMS-Enrolled Retail Pharmacies

Major chains including CVS, Walgreens, and Publix carry flibanserin at locations in Florida, though individual stores may need to order it if it is not in stock. All dispensing pharmacies must complete REMS enrollment before filling a flibanserin prescription [3]. Patients can call ahead to confirm REMS status and stock availability.

Mail-Order and Specialty Pharmacies

Several mail-order pharmacies ship flibanserin to Florida addresses within 2-3 business days. Hims and Hers Pharmacy, Truepill, and other telehealth-affiliated pharmacies maintain REMS enrollment and can dispense directly after an approved telehealth consult. Shipping to any Florida zip code is permitted because Florida has not enacted legislation restricting mail-order delivery of this medication.

503A Compounding Pharmacies

Florida 503A pharmacies operate under the Florida Board of Pharmacy and are licensed to compound flibanserin into alternative formulations (for example, lower doses or cream preparations) on a patient-specific prescription basis. The FDA's definition of a 503A pharmacy limits compounding to non-commercially available dosage forms or to patients with documented needs that the commercial product cannot meet [9]. Because Addyi is commercially available as a 100 mg tablet, a Florida 503A pharmacy may compound flibanserin only if there is a specific medical reason documented in the prescription (such as a patient needing a 50 mg titration dose for tolerability). The Florida Department of Health enforces these restrictions through the Board of Pharmacy's inspection program.

Compounded flibanserin is not covered by any insurer and is not FDA-approved, which means the quality and bioavailability of compounded preparations have not been evaluated in clinical trials. Patients choosing compounded flibanserin should use a Florida-licensed 503A pharmacy with USP 795/800 certification.

Insurance Coverage and Cost in Florida

Florida Medicaid does not cover Addyi for HSDD. Commercial insurance coverage varies widely. A 2022 analysis published in JAMA Network Open found that coverage of FDA-approved medications for female sexual dysfunction lagged significantly behind coverage of analogous drugs approved for male sexual dysfunction, with many plans excluding flibanserin outright [10].

Without insurance, a 30-day supply of Addyi typically retails for $800-$900 at Florida pharmacies. Sprout Pharmaceuticals offers a manufacturer savings card that can reduce the out-of-pocket cost to as low as $99 per month for commercially insured patients and $200 per month for cash-pay patients who qualify. The card is available at AddyiSavings.com and does not require a specific insurer.

Some Florida Blue Cross Blue Shield and Cigna plans cover flibanserin with prior authorization. Prior authorization typically requires:

1. A documented HSDD diagnosis using DSM-5 criteria (F52.0).
2. Evidence that secondary causes (depression, hypothyroidism, medication side effects) have been evaluated and addressed.
3. A statement that the patient is premenopausal.
4. In some plans, documentation that the patient tried and failed a therapeutic trial of couples counseling or sex therapy.

The prior authorization appeal process in Florida is governed by the Florida Patient's Bill of Rights (Florida Statute 641.3155), which requires insurers to respond to standard prior authorization requests within 3 business days and to urgent requests within 72 hours.

Alcohol Restriction and REMS: What Florida Patients Must Know

The Addyi REMS program exists specifically because of the drug-alcohol interaction. When flibanserin 100 mg is taken with alcohol, blood pressure can drop to dangerous levels. A pharmacokinetic study published in Clinical Pharmacology and Therapeutics (N=25) found that co-administration of flibanserin with ethanol produced a mean maximum systolic BP decrease of 26 mmHg compared to 6 mmHg with flibanserin alone [11]. Two participants in that study experienced syncopal episodes.

The FDA label states clearly: "Advise patients to avoid alcohol use while taking Addyi. The risk of hypotension and syncope is increased when Addyi is taken with alcohol" [3]. This is not a soft recommendation. Patients who consume alcohol regularly should discuss this restriction honestly with their provider before starting therapy, because the benefit-risk calculation changes if consistent abstinence is not achievable.

Strong CYP3A4 inhibitors, including fluconazole, ketoconazole, clarithromycin, and grapefruit juice, are contraindicated with flibanserin because they can raise flibanserin plasma concentrations by up to 4.5-fold, compounding hypotension risk [3]. Moderate CYP3A4 inhibitors such as fluoxetine require caution. Patients on multiple medications should bring a complete medication list to the prescribing consult.

Efficacy: What Florida Patients Should Realistically Expect

The three key trials supporting FDA approval, including BEGONIA and two additional trials (VIOLET and DAISY), enrolled a combined total of approximately 2,400 premenopausal women over 24-week periods [1, 2]. The composite results showed:

• A mean increase of 0.5-1.0 satisfying sexual events per month above placebo.
• A mean reduction of 10-15 points on the Female Sexual Distress Scale-Revised (FSDS-R, scale 0-60) compared to 7-10 points for placebo.
• Response rates (defined as a clinically meaningful improvement) of approximately 50% versus 35% for placebo [1].

These numbers are modest. Flibanserin is not a drug with a dramatic effect size in every patient. About one in three women who respond do so robustly, reporting 2 or more additional satisfying sexual events per month. The remaining responders notice a subtler improvement in desire and distress. Clinical guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) recommend flibanserin as a first-line pharmacological option for premenopausal HSDD while acknowledging the modest average effect size and the importance of patient counseling about realistic expectations [12].

If no improvement is observed after 8 weeks of consistent nightly dosing at 100 mg, the FDA label recommends discontinuation [3]. The drug is not effective for everyone, and early discontinuation is appropriate rather than continued use without benefit.

Transferring an Existing Addyi Prescription to Florida

Patients who move to Florida with an existing flibanserin prescription from another state may transfer it to a REMS-enrolled Florida pharmacy under standard pharmacy transfer rules, provided the prescription has remaining refills and was issued by a licensed prescriber. Florida does not impose additional state-level restrictions on transferring non-controlled prescriptions.

If the original prescription was written by an out-of-state prescriber who is not licensed in Florida or does not hold a Florida telehealth registration, a new prescription from a Florida-licensed provider is required. The new provider will need to complete a brief re-evaluation to confirm the HSDD diagnosis remains appropriate and to update the REMS Patient-Prescriber Agreement. Most telehealth platforms can complete this re-evaluation in a single asynchronous or synchronous visit.

Patients transferring to a 503A compounding pharmacy in Florida from a compounding pharmacy in another state will need a new prescription, as compound prescriptions cannot be transferred between pharmacies under federal USP and FDA compounding guidelines [9].